Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Jimenez

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
British Journal of Haematology|February 9, 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group databaseVictor H Jimenez-Zepeda, Christopher Venner, Arleigh McCurdy, et al.
Ejhaem|December 5, 2022
Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort studyVictor H Jimenez-Zepeda, Donna Reece, Rodrigo Rigo, et al.
Blood Advances|May 3, 2019
Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulinRosy Dabas, Kareem Jamani, Shahbal B Kangarloo, et al.
Blood|January 14, 2014
Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United StatesOana M Mereuta, Jason D Theis, Julie A Vrana, et al.
Annals of Clinical and Translational Neurology|April 14, 2025
ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia GravisAli A Habib, Kristl G Claeys, Vera Bril, et al.
Journal of Medicinal Chemistry|August 24, 2013
Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myelomaBrent D G Page, Danielle C Croucher, Zhi Hua Li, et al.
The New Phytologist|April 9, 2026
Weaponizing nutrition: plants use a double strategy to fight herbivory, converting nutritionally essential fatty acids into defensive oxylipin signalsGuillermo H Jimenez-Aleman, Santiago Michavila, Francisco Medina Paz, et al.
Cancer Medicine|September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group DatabaseHira Mian, Richard LeBlanc, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group DatabaseHira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
British Journal of Haematology|February 9, 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group databaseVictor H Jimenez-Zepeda, Christopher Venner, Arleigh McCurdy, et al.
Ejhaem|December 5, 2022
Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort studyVictor H Jimenez-Zepeda, Donna Reece, Rodrigo Rigo, et al.
Blood Advances|May 3, 2019
Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulinRosy Dabas, Kareem Jamani, Shahbal B Kangarloo, et al.
Blood|January 14, 2014
Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United StatesOana M Mereuta, Jason D Theis, Julie A Vrana, et al.
Annals of Clinical and Translational Neurology|April 14, 2025
ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia GravisAli A Habib, Kristl G Claeys, Vera Bril, et al.
Journal of Medicinal Chemistry|August 24, 2013
Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myelomaBrent D G Page, Danielle C Croucher, Zhi Hua Li, et al.
The New Phytologist|April 9, 2026
Weaponizing nutrition: plants use a double strategy to fight herbivory, converting nutritionally essential fatty acids into defensive oxylipin signalsGuillermo H Jimenez-Aleman, Santiago Michavila, Francisco Medina Paz, et al.
Cancer Medicine|September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group DatabaseHira Mian, Richard LeBlanc, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group DatabaseHira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
Pageof 16